Pre-Open Stock Movers 03/11: (SIEB) (VIR) (RBLX) Higher; (ALTO) (SUMO) (ORCL) Lower (more...)
- Wall Street ends volatile week sharply higher
- AT&T (T) in Talks to Merge Media Assets with Discovery (DISCA) - WSJ
- Disney (DIS) Dips As Streaming Business Shows Signs of Slowing Down, Analysts 'Very Bullish' on LT Opportunity
- Airbnb (ABNB) Bookings Up 52% to Help Sales Beat, Seen as a 'Blow Out Quarter' as More Upside is Left
- DoorDash (DASH) Reports Bigger Loss and a Sales Beat, Shares Soars on Strong Guidance and Two Upgrades to 'Buy'
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Today's Pre-Open Stock Movers:
Siebert Financial Corp. (NASDAQ: SIEB) 59.3% HIGHER; Revenue approximately doubled to $54.9 million in 2020 compared to $28.6 million in 2019, largely due to recent acquisitions.
Vir Biotechnology, Inc. (Nasdaq: VIR) 49% HIGHER; VIR and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that an Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) trial evaluating VIR-7831 (GSK4182136) as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalization be stopped for enrollment due to evidence of profound efficacy.
AVEO Oncology (Nasdaq: AVEO) 27% HIGHER; added to 89% intra-day gain after it announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA® (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies. FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
Spectrum Pharmaceuticals (Nasdaq: SPPI) 23% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for poziotinib for the treatment of non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 mutations. Spectrum plans to submit a new drug application (NDA) for poziotinib later this year.
Alto Ingredients, Inc. (NASDAQ: ALTO) 16.7% LOWER; Net sales were $168.8 million, compared to $357.6 million. Net loss available to common stockholders was $20.5 million, or $0.30 per share, and included an impairment charge of $24.4 million related to the company’s Western assets. This compares to a loss of $41.4 million, or $0.85 per share, for the three months ended December 31, 2019.
NV5 Global, Inc. (NASDAQ: NVEE) 12.7% LOWER; announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price of $93.00 per share
Cloudera Inc. (NYSE: CLDR) 10% LOWER; reported Q4 EPS of $0.15, $0.04 better than the analyst estimate of $0.11. Revenue for the quarter came in at $226.56 million versus the consensus estimate of $221.43 million. Cloudera Inc. sees Q1 2022 EPS of $0.07-$0.09, versus the consensus of $0.10. Cloudera Inc. sees Q1 2022 revenue of $216-218 million, versus the consensus of $226.81 million. Cloudera Inc. sees FY2022 EPS of $0.35-$0.39, versus the consensus of $0.41. Cloudera Inc. sees FY2022 revenue of $907-927 million, versus the consensus of $947.63 million.
Kadmon Holdings, Inc. (NASDAQ: KDMN) 9.8% LOWER; announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for belumosudil for the treatment of chronic graft-versus-host disease (cGVHD). In a notice received from the FDA on March 9, 2021, the Company was informed that the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of belumosudil has been extended to August 30, 2021.
Roblox Corporation (NYSE: RBLX) 8.5% HIGHER; yesterday's IPO adds to gains, ARK buys 500K shares
GameStop Corp. (NYSE: GME) 7.7% LOWER; gives back some recent gains.
AMC Entertainment (NYSE: AMC) 7.6% HIGHER; reported Q4 EPS of ($3.15), in-line with the analyst estimate of ($3.15). Revenue for the quarter fell 88.8% to $162.5 million but beat the consensus estimate of $142.35 million. Cash at December 31, 2020 was $308.3 million excluding restricted cash of $13.1 million. U.S. attendance was down 92.3% in the quarter.
Sumo Logic Inc. (NASDAQ: SUMO) 7.4% LOWER; reported Q4 EPS of ($0.07), $0.05 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $54.2 million versus the consensus estimate of $52.14 million. Sumo Logic Inc. sees Q1 2022 EPS of ($0.12), versus the consensus of ($0.14). Sumo Logic Inc. sees Q1 2022 revenue of $53.2-54.2 million, versus the consensus of $53.4 million. Sumo Logic Inc. sees FY2022 EPS of ($0.50)-($0.48), versus the consensus of ($0.51). Sumo Logic Inc. sees FY2022 revenue of $231-235 million, versus the consensus of $234.08 million.
Bumble (NASDAQ: BMBL) 6.8% HIGHER; reported Q4 EPS of ($0.01), versus $0.00 reported last year. Revenue for the quarter rose 31.1% to $165.6 million, versus $126.3 million reported last year. Bumble sees Q1 2021 revenue of $163-165 million.
NIO Limited (NYSE: NIO) 6.5% HIGHER; Mizuho initiates with a Buy rating and $60 price target.
Oracle (NYSE: ORCL) 6% LOWER; reported Q3 EPS of $1.16, $0.05 better than the analyst estimate of $1.11. Revenue for the quarter came in at $10.1 billion versus the consensus estimate of $10.07 billion. Sees Q4 Revenue Growing 5% to 7% in U.S. Dollars. Sees Q4 EPS of $1.28 to $1.32 in U.S. Dollars vs Consensus of $1.28.
Party City (NYSE: PRTY) 5.8% LOWER; reported Q4 EPS of $0.25, $0.06 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $648.2 million versus the consensus estimate of $648.25 million. Party City sees Q1 2021 revenue of $397-410 million, versus the consensus of $425.75 million.
Asana, Inc. (NYSE: ASAN) 5.8% HIGHER; reported Q4 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $62.68 million.
Tesla (NASDAQ: TSLA) 4.2% HIGHER; Mizuho initiates at Buy, raising prices on some models.
MGM Growth Properties LLC (NYSE: MGP) 2.8% LOWER; commenced an underwritten public offering of 19,000,000 Class A shares. As part of the offering, the Company also intends to grant the underwriters a 30-day over-allotment option to purchase up to an additional 2,850,000 shares from the Company.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 05/13: (AMRK) (SI) (SONO) Higher; (WISH) (POSH) (TDUP) Lower (more...)
- Strongbridge Biopharma (SBBP) Announces FDA Filing Acceptance of NDA for RECORLEV for Treatment of Endogenous Cushing’s Syndrome
- Pre-Open Stock Movers 05/11: (FOE) (CERC) (UFS) Higher; (JMIA) (RXT) (SPCE) Lower (more...)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesRaising Prices, Tesla, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, IPO, Pre Market Movers, PDUFA, FDA, ARK
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!